CSL

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

News

FDA green lights CSL's once-monthly HAE drug Andembry

CSL has won FDA approval for Andembry, its once-monthly subcutaneous drug to prevent hereditary angioedema (HAE) attacks.

News

First self-amplifying mRNA vaccine reaches Europe

Arcturus Therapeutics and CSL's COVID-19 vaccine Kostaive is the first in the new sa-mRNA class to be approved for marketing in the EU.

News

EU approves CSL's once-monthly HAE drug Andembry

The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.

Astellas bets on Vir cancer drug, and other licensing deals

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL will slash headcount and hive off vaccine business

FDA green lights CSL's once-monthly HAE drug Andembry

First self-amplifying mRNA vaccine reaches Europe

EU approves CSL's once-monthly HAE drug Andembry

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

CSL

Editor's Picks